

# **Certificate of Analysis for NR-48978**

#### Klebsiella pneumoniae, Strain 1.53

### Catalog No. NR-48978

**Product Description:** *Klebsiella pneumoniae* (*K. pneumoniae*), strain 1.53 was isolated in 2009 in India, from an intra-abdominal infection of a human patient.

Lot<sup>1</sup>: 63431906 Manufacturing Date: 10APR2015

TEST	SDECIFICATIONS	DECLUTE
TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology <sup>2</sup>	Report results	Circular, convex, entire, smooth and
		gray (Figure 1)
Motility (wet mount)	Report results	Non-motile
VITEK® MS (MALDI-TOF)	Consistent with K. pneumoniae	Consistent with K. pneumoniae
Antibiotic Susceptibility Profile		
VITEK <sup>®</sup> (AST-GN69) <sup>3</sup> ESBL <sup>4</sup>		
	Report results	Positive
Ampicillin	Resistant	Resistant (≥ 32 µg/mL)
Amoxicillin/Clavulanic Acid	Resistant	Resistant (≥ 32 µg/mL)
Ampicillin/Sulbactam	Report results	Resistant (≥ 32 µg/mL)
Piperacillin/Tazobactam	Report results	Resistant (≥ 128 μg/mL)
Cefazolin	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (= 16 μg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Cefepime	Resistant	Resistant (= 32 μg/mL)
Ertapenem	Report results	Sensitive (≤ 0.5 μg/mL)
Imipenem	Report results	Sensitive (≤ 0.25 µg/mL) <sup>5</sup>
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Tobramycin	Report results	Resistant (≥ 16 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 µg/mL)
Trimethoprim/Sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
VITEK® (AST-XN06) <sup>3</sup>	<b>.</b>	
Ticarcillin	Report results	Resistant (≥ 128 µg/mL)
Piperacillin	Report results	Resistant (≥ 128 µg/mL)
Cefalotin	Resistant	Resistant (≥ 64 µg/mL)
Cefuroxime	Resistant	Resistant (≥ 64 µg/mL)
Cefuroxime Axetil	Report results	Resistant (≥ 64 µg/mL)
Cefotetan	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Resistant	Resistant (≥ 64 µg/mL)
Cefpodoxime	Report results	Resistant (≥ 8 µg/mL)
Cefotaxime	Resistant	Resistant (≥ 64 µg/mL)
Ceftizoxime	Report results	Resistant (≥ 64 µg/mL)
Aztreonam	Report results	Resistant (≥ 64 µg/mL)
Doripenem	Report results	Resistant (≥ 8 μg/mL)
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Amikacin	Resistant	Resistant (≥ 64 µg/mL)
Nalidixic Acid	Resistant	Resistant (≥ 32 µg/mL)
Moxifloxacin Norfloxacin	Report results	Resistant (≥ 8 µg/mL)
	Report results Resistant	Resistant (≥ 16 µg/mL)
Tetracycline Tigecycline		Resistant (≥ 16 µg/mL)
rigecycline	Report results	Resistant (≥ 8 µg/mL)

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898




#### SUPPORTING INFECTIOUS DISEASE RESEARCH

## **Certificate of Analysis for NR-48978**

TEST	SPECIFICATIONS	RESULTS
Etest <sup>®</sup> antibiotic test strips <sup>6</sup> Chloramphenicol <sup>7</sup>	Resistant	Resistant (> 256 μg/mL)
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (1490 base pairs)	Consistent with K. pneumoniae	Consistent with <i>K. pneumoniae</i> <sup>8</sup>
Purity (post-freeze) <sup>9</sup>	Consistent with K. pneumoniae	Consistent with K. pneumoniae
Viability (post-freeze) <sup>2</sup>	Growth	Growth

<sup>&</sup>lt;sup>1</sup>K. pneumoniae, strain 1.53 was deposited by Marcelo Tolmasky, Ph.D., Professor, Center for Applied Biotechnology Studies, California State University Fullerton, Fullerton, California, USA. NR-48978 was produced from a frozen subculture of the deposited material. The subculture was cultivated in Tryptic soy broth for 23 hours at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic soy agar with 5% defibrinated sheep blood kolles which were grown 23 hours at 37°C in an aerobic atmosphere to produce this lot.

Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere on Tryptic soy agar with 5% defibrinated sheep blood.



**Date: 15 JUL 2015** 

Signature:

**BEI Resources Authentication** 

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC® s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

<sup>&</sup>lt;sup>2</sup>25 hours at 37°C in an aerobic atmosphere on Tryptic soy agar with 5% defibrinated sheep blood

<sup>&</sup>lt;sup>3</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S22 (2012)

<sup>&</sup>lt;sup>4</sup>The VITEK<sup>®</sup>2 ESBL Test is a confirmatory test for Extended-Spectrum Beta-Lactamases (ESBLs) inhibited by clavulanic acid and utilizes cefepime, cefotaxime and ceftazidime, with and without clavulanic acid, to determine a positive or negative result.

<sup>&</sup>lt;sup>5</sup>K. pneumoniae, strain 1.53 was deposited as being resistant to imipenem. Antibiotic susceptibility testing performed in duplicate determined that strain 1.53 is susceptible to imipenem.

<sup>&</sup>lt;sup>6</sup>24 hours at 37°C in an aerobic atmosphere on Mueller Hinton agar

<sup>&</sup>lt;sup>7</sup>For chloramphenicol (bioMérieux Etest<sup>®</sup> 412308), a MIC ≤ 8 μg/mL is sensitive, a MIC = 16 μg/mL is intermediate and a MIC ≥ 32 μg/mL is resistant.

<sup>&</sup>lt;sup>8</sup>Also consistent with other *Klebsiella* species